APREA THERAPEUTICS, INC. (APRE) Social Stream
Featured Post From StockTwits About APRE
$APRE this strong progress in aml trials is what you need to pay attention to! Guess what we have a orphan designation in AML. Phase 3 trial was on MDS not AML. Orphan designation have been approved without phase 3 studies in the past so to those saying that this company doesnt have a opportunity to bring a drug to the market for along time has no clue what they are talking about. Look at the past comparison numbers of different trials of post stem cell transplant with different drug and compare to pur study number are out of this world number or should i say "knock your socks off numbers". Youre focusing on a misdosed trial on MDS when discounting how good the numbers are on the AML trials the company even touts there progress on AML while all youre blindsided by Mds trial numbers.Christianmurray, published August 15, 2021
Loading social stream, please wait...